Naghavi Morteza, Falk Erling, Hecht Harvey S, Shah Prediman K
Association for Eradication of Heart Attack, Houston, Texas 77005, USA.
Crit Pathw Cardiol. 2006 Dec;5(4):187-90. doi: 10.1097/01.hpc.0000249784.29151.54.
Atherosclerotic cardiovascular disease (A-CVD) is preventable. Major causal risk factors are known, and effective and safe treatments exist. However, A-CVD remains the leading cause of death and severe disability not only in affluent countries, but also globally. The burden of A-CVD is growing faster in poor and developing countries threatening their future economic development. Traditional methods for prevention of A-CVD have proven largely insufficient. Although many societal factors contribute to the epidemic of A-CVD (eg, smoking, obesity, diabetes, insufficient physical activity, and so on) and deserve renewed attention, early detection of the asymptomatic vulnerable patient who has significant subclinical atherosclerosis presents as a low hanging fruit in primary prevention of A-CVD. The Screening for Heart Attack Prevention and Education (SHAPE) Task Force, comprised of an international group of experts, has proposed the First SHAPE Guideline to address a major shortcoming in the existing guidelines in primary prevention of A-CVD. It is based on the observation that most heart attacks and strokes occur in people who are not classified as high risk by the traditional risk factor-based approach recommended in the United States (Framingham Risk Score) and Europe (SCORE). Unfortunately, these guidelines provide inadequate warning to asymptomatic individuals with subclinical atherosclerosis who are unaware of their high-risk status and are not aggressively treated by their physicians who follow the existing recommendations. Consequently, most of these asymptomatic individuals, who are vulnerable to a near-future heart attack, are not offered the benefit of existing prophylactic therapies. Unlike decades ago when screening for risk factors of A-CVD was the only available risk stratification method in primary prevention, today, noninvasive detection of atherosclerosis is feasible and widely available. It provides a direct and individualized method for risk assessment. A large body of evidence has been compiled in recent years showing the superior prognostic value of detecting atherosclerosis rather than risk factors of atherosclerosis. The First SHAPE Guideline calls for noninvasive screening of all asymptomatic men 45 to 75 years old and asymptomatic women 55 to 75 years old (except those defined as very low risk) to detect and treat individuals with subclinical atherosclerosis. The intensity of treatment should correlate with the severity of the disease. Among existing tools for detection of subclinical atherosclerosis, the SHAPE Task Force has created the SHAPE Flow Chart based on the following 2 noninvasive imaging techniques: coronary artery calcium scoring using computed tomography and carotid intima media thickness and plaque using B-mode ultrasonography.
动脉粥样硬化性心血管疾病(A-CVD)是可预防的。主要的致病风险因素已知,且存在有效且安全的治疗方法。然而,A-CVD不仅在富裕国家,而且在全球范围内仍然是导致死亡和严重残疾的主要原因。在贫穷和发展中国家,A-CVD的负担增长更快,威胁着它们未来的经济发展。传统的A-CVD预防方法已被证明在很大程度上是不够的。尽管许多社会因素促成了A-CVD的流行(如吸烟、肥胖、糖尿病、体育活动不足等),值得重新关注,但早期发现有明显亚临床动脉粥样硬化的无症状易患患者是A-CVD一级预防中容易实现的目标。由一组国际专家组成的心脏病发作预防与教育筛查(SHAPE)特别工作组提出了首份SHAPE指南,以解决现有A-CVD一级预防指南中的一个主要缺陷。该指南基于这样的观察结果:大多数心脏病发作和中风发生在那些按照美国(弗雷明汉风险评分)和欧洲(SCORE)推荐的基于传统风险因素的方法未被归类为高危的人群中。不幸的是,这些指南没有对患有亚临床动脉粥样硬化但未意识到自己高危状态的无症状个体提供充分的警示,而遵循现有建议的医生也没有对他们进行积极治疗。因此,这些大多数易在近期发生心脏病发作的无症状个体无法从现有的预防性治疗中获益。与几十年前A-CVD风险因素筛查是一级预防中唯一可用的风险分层方法不同,如今,动脉粥样硬化的无创检测是可行且广泛可用的。它提供了一种直接且个性化的风险评估方法。近年来已积累了大量证据,表明检测动脉粥样硬化而非动脉粥样硬化风险因素具有更高的预后价值。首份SHAPE指南呼吁对所有45至75岁的无症状男性和55至75岁的无症状女性(除那些被定义为极低风险者外)进行无创筛查,以检测和治疗患有亚临床动脉粥样硬化的个体。治疗强度应与疾病严重程度相关。在现有的亚临床动脉粥样硬化检测工具中,SHAPE特别工作组基于以下两种无创成像技术创建了SHAPE流程图:使用计算机断层扫描进行冠状动脉钙化评分,以及使用B型超声检查测量颈动脉内膜中层厚度和斑块。